Kamada Secures $25M Contract to Supply KAMRAB® and VARIZIG® in Latin America

A global leader in biopharmaceuticals specializing in rare and serious conditions, has announced a major three-year supply contract with an international organization for its proprietary products, KAMRAB® and VARIZIG®, targeting the Latin American market. The contract, spanning 2025–2027, is valued at approximately $25 million, with anticipated revenue for 2025 already integrated into Kamada’s previously disclosed revenue guidance for the year.

A Testament to Kamada’s Global Reach

Amir London, Kamada’s CEO, emphasized the strategic importance of this agreement, stating, “We are extremely pleased with this significant three-year supply agreement, which we believe validates the global strength of our leading specialty immunoglobulin portfolio and supports our expected multi-year growth outlook.” London highlighted the achievement as a reflection of Kamada’s capability to expand beyond traditional markets like the U.S. and Canada, focusing on securing contracts in other strategic regions.

Product Portfolio Overview

The awarded contract centers on Kamada’s flagship products:

• KAMRAB®, a specialty immunoglobulin used for passive, short-term prevention of rabies infection. Administered post-exposure, it is crucial in cases involving rabid or potentially rabid animal contact.
• VARIZIG®, a Varicella Zoster Immune Globulin (Human), is designed for post-exposure prophylaxis in high-risk individuals, offering critical protection against complications from varicella (chickenpox) exposure.

These products underscore Kamada’s commitment to addressing unmet medical needs with specialty immune globulins that provide life-saving treatment in emergency scenarios.

Strategic Implications

This multi-year agreement highlights Kamada’s robust commercial capabilities and its potential to penetrate international markets. It also demonstrates the growing recognition of Kamada’s specialty plasma-derived products and reinforces the company’s position as a leader in the biopharmaceutical field. By leveraging this success, Kamada aims to strengthen its presence in key global markets while pursuing additional partnerships to support its growth trajectory.